Eloxatin is a drug owned by Sanofi Aventis Us Llc. It is protected by 8 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 09, 2017. Details of Eloxatin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5420319 (Pediatric) | Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same |
Feb, 2017
(7 years ago) |
Expired
|
| US5420319 | Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same |
Aug, 2016
(8 years ago) |
Expired
|
|
US5716988 (Pediatric) | Pharmaceutically stable preparation of oxaliplatinum |
Feb, 2016
(8 years ago) |
Expired
|
| US5716988 | Pharmaceutically stable preparation of oxaliplatinum |
Aug, 2015
(9 years ago) |
Expired
|
|
US5338874 (Pediatric) | Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity |
Oct, 2013
(11 years ago) |
Expired
|
|
US5290961 (Pediatric) | Platinum compound and process of preparing same |
Jul, 2013
(11 years ago) |
Expired
|
| US5338874 | Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity |
Apr, 2013
(11 years ago) |
Expired
|
| US5290961 | Platinum compound and process of preparing same |
Jan, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Eloxatin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Eloxatin's family patents as well as insights into ongoing legal events on those patents.
Eloxatin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Eloxatin's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 09, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Eloxatin Generic API suppliers:
Oxaliplatin is the generic name for the brand Eloxatin. 20 different companies have already filed for the generic of Eloxatin, with Fresenius Kabi Usa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Eloxatin's generic
How can I launch a generic of Eloxatin before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Eloxatin's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Eloxatin's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Eloxatin -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 5 mg/mL, 10 mL and 20 mL vials | 09 Feb, 2007 | 11 | 07 Aug, 2009 | 09 Feb, 2017 | Eligible |
| 5 mg/mL, 40 mL vials | 16 Jul, 2007 | 1 | 07 Aug, 2015 | Extinguished |
About Eloxatin
Eloxatin is a drug owned by Sanofi Aventis Us Llc. It is used for treating symptoms of depression, anxiety disorders, panic disorders, and certain types of pain. Eloxatin uses Oxaliplatin as an active ingredient. Eloxatin was launched by Sanofi Aventis Us in 2005.
Approval Date:
Eloxatin was approved by FDA for market use on 31 January, 2005.
Active Ingredient:
Eloxatin uses Oxaliplatin as the active ingredient. Check out other Drugs and Companies using Oxaliplatin ingredient
Treatment:
Eloxatin is used for treating symptoms of depression, anxiety disorders, panic disorders, and certain types of pain.
Dosage:
Eloxatin is available in injectable form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG/20ML (5MG/ML) | INJECTABLE | Discontinued | INTRAVENOUS |
| 100MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INJECTABLE | Discontinued | INTRAVENOUS |
| 50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INJECTABLE | Discontinued | INTRAVENOUS |
| 50MG/10ML (5MG/ML) | INJECTABLE | Discontinued | INTRAVENOUS |
| 200MG/40ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | INJECTABLE | Discontinued | INTRAVENOUS |